Himanshu Patni

 The increasing prevalence of cancer is a significant driver for the growth of the intratumoral cancer therapies market . Cancer remains one of the leading causes of morbidity and mortality worldwide, with a rising number of new cases diagnosed each year. As the incidence of various cancer types continues to surge, there is a growing demand for innovative and effective treatment options, including intratumoral therapies. Furthermore, traditional treatment modalities, such as surgery, chemotherapy, and radiation therapy, have been the mainstays of cancer treatment for decades. In recent years, there have been notable advancements and developments in the field of intratumoral cancer therapies, driven by both research institutions and pharmaceutical companies. These developments have further fueled the market's growth potential. For instance, in 2020, Tizona Therapeutics received a significant investment from AbbVie to support the development of its intratumoral immunotherapy programs...